Obefazimod for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease by a colonoscopy and biopsy.
- Your Crohn's is moderate to severe, meaning you have certain symptoms and inflammation seen on a colonoscopy.
- You have tried at least one standard treatment (like steroids, immunosuppressants, or a biologic) and it didn't work well enough or you couldn't take it.
- You do not have an active infection, a colostomy bag, or a history of certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new form of the medicine obefazimod (a tiny tablet) is absorbed by the body, and whether people find it easy to take. It is for healthy adults ages 18–55 who are not taking other medications and are generally well.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Hear when a new Moderately to Severely Active Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.